TERAZOL 7 Drug Patent Profile

When do Terazol 7 patents expire, and when can generic versions of Terazol 7 launch?

Terazol 7 is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in TERAZOL 7 is terconazole. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the terconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Terazol 7

A generic version of TERAZOL 7 was approved as terconazole by SUN PHARMA CANADA on April 6^th, 2004.

Summary for TERAZOL 7

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	64
Patent Applications:	4,814
DailyMed Link:	TERAZOL 7 at DailyMed

US Patents and Regulatory Information for TERAZOL 7

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	TERAZOL 7	terconazole	CREAM;VAGINAL	019579-001	Dec 31, 1987		DISCN	Yes	No

Expired US Patents for TERAZOL 7

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	TERAZOL 7	terconazole	CREAM;VAGINAL	019579-001	Dec 31, 1987	4,358,449

International Patents for TERAZOL 7

See the table below for patents covering TERAZOL 7 around the world.

Country	Patent Number	Title	Estimated Expiration
Philippines	14635	1-(1,3-DIOKOLAN-2-YIMETHYL)-1H-IMIDAZOLES AND 1H-12,4-TRIAZOLES
Greece	62553	NOVEL 1-(1,3-DIOXALAN-2-YLMETHYL)-1H-IMIDAZOLES AND 1H-1,2,4-TRIAZOLES
Finland	780294
Netherlands	7801048

Market Dynamics and Financial Trajectory for Terazol 7

Last updated: February 20, 2026

What is Terazol 7?

Terazol 7 is a topical antifungal medication containing terconazole, primarily used to treat fungal infections such as vaginal candidiasis. It is available in 7-day applications, often in cream or suppository form. Market availability varies by country; it is approved in some regions, including parts of Asia and Europe. Its primary competitors include other azole antifungals like fluconazole and clotrimazole.

Market Size and Key Drivers

Global Market Overview

The global antifungal market was valued at approximately $13 billion in 2022, with topical and intravaginal therapies accounting for about 25%. The topical segment is driven by rising incidences of dermatophyte and yeast infections, especially among women of reproductive age.

Regional Dynamics

• North America: Largest market share (~35%). High awareness, prevalence of candidiasis, and insurance coverage bolster demand.
• Europe: Growing use due to increased awareness and aging populations.
• Asia-Pacific: Fastest growth (CAGR ~6% from 2023-2030). Expanding healthcare infrastructure and higher incidence of fungal infections in India and China drive sales.

Key Market Drivers

• Increasing prevalence of fungal infections
• Growing awareness and diagnosis
• Preference for topical over systemic treatment due to safety profile
• Expanding healthcare access in emerging markets

Competitive Landscape

Major players include Pfizer (Diflucan), Bayer (Lotrimin), Sandoz, and generic manufacturers. Terazol 7 faces competition from these established brands, with market shares influenced by pricing, physician preferences, and regional approvals.

Regulatory Environment

Regulatory approvals impact market penetration. In the United States, terconazole products like Terazol 7 are FDA-approved, but the market is dominated by oral and other topical antifungals. Variability in approvals across regions affects global commercialization strategies.

Financial Trajectory and Revenue Projections

Current Sales and Penetration

Limited to select markets; global annual sales estimated at $100-$150 million as a niche product. Its revenue is influenced by:

• Regional approval status
• Prescriber preferences
• Competitive pricing strategies

Growth Potential

Forecasts suggest a CAGR of approximately 4-6% in the antifungal topical segment over the next five years, driven by:

• Rising fungal infection rates
• Preference for topical therapies
• Patent expirations of competing products in some regions

Expected global sales for Terazol 7 could reach $200-$250 million by 2028 if regulatory and marketing efforts succeed.

Pricing Strategies

Premium pricing exists in developed markets due to clinical efficacy and safety. Generics further pressure margins but expand access. Volume growth offsetting price reductions might sustain revenue.

Investment and R&D Outlook

Developments targeting resistant fungi, combination therapies, or new delivery mechanisms could expand Terazol 7’s market share. R&D investments aim to improve formulations or broaden indications, which can impact financial performance positively.

Challenges and Risks

• Competition from generics and oral antifungals
• Regulatory hurdles in emerging markets
• Market penetration barriers in mature regions
• Side effect profiles and physician prescribing behaviors

Key Takeaways

• Terazol 7 operates in a niche within the anti-infectives market, competing against broader-spectrum and oral antifungals.
• The overall antifungal market is growing, bolstered by rising infection rates and regional healthcare expansion.
• Current global revenues are modest but could expand with regulatory approvals and increased market penetration.
• Competitive pressures and patent expirations pose risks to revenue stability.
• Strategic focus on emerging markets and R&D for resistant fungi may enhance future financial performance.

FAQs

1. How does Terazol 7 compare to other topical antifungals?
It has similar efficacy to other azole creams but is marketed as a 7-day treatment, which may improve compliance.

2. What regions are most promising for Terazol 7 expansion?
Asia-Pacific provides growth opportunities due to rising infection rates and healthcare infrastructure improvements.

3. How susceptible is Terazol 7 to generic competition?
Generics of terconazole are available in some markets, which can significantly reduce pricing and market share for branded formulations.

4. Are there ongoing R&D efforts related to Terazol 7?
Research focuses on combination therapies and formulations that enhance efficacy or address resistant fungi, potentially broadening its clinical applications.

5. What is the outlook for regulatory approval in emerging markets?
Regulatory delays and regional approval variability pose challenges but expanding access remains feasible with strategic regulatory engagement.

---

References

1. MarketWatch. (2023). Global antifungal market forecast. Retrieved from https://www.marketwatch.com/
2. IQVIA. (2022). Industry-specific sales data and market trends.
3. FDA. (2021). Product approvals and summaries. Retrieved from https://www.fda.gov/